DBV Technologies (NASDAQ:DBVT) Downgraded to Sell Rating by Wall Street Zen

by · The Cerbat Gem

Wall Street Zen lowered shares of DBV Technologies (NASDAQ:DBVT – Free Report) from a hold rating to a sell rating in a report issued on Saturday.

Several other equities analysts have also weighed in on the company. Cantor Fitzgerald set a $48.00 price target on DBV Technologies in a research note on Wednesday, December 17th. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. HC Wainwright set a $40.00 price target on shares of DBV Technologies in a research note on Thursday, December 18th. Finally, Citizens Jmp boosted their price objective on DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, DBV Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.38.

View Our Latest Report on DBV Technologies

DBV Technologies Price Performance

NASDAQ:DBVT opened at $21.61 on Friday. The firm has a market capitalization of $867.86 million, a P/E ratio of -4.18 and a beta of -1.17. DBV Technologies has a 1-year low of $3.80 and a 1-year high of $26.18. The company’s fifty day moving average price is $18.47 and its 200-day moving average price is $13.99.

Insider Transactions at DBV Technologies

In other news, major shareholder Bpifrance Epic sold 2,076,990 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $4.85, for a total value of $10,073,401.50. Following the completion of the sale, the insider directly owned 8,595,472 shares of the company’s stock, valued at approximately $41,688,039.20. This represents a 19.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.44% of the company’s stock.

Hedge Funds Weigh In On DBV Technologies

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vivo Capital LLC purchased a new position in DBV Technologies during the second quarter worth about $9,659,000. Adage Capital Partners GP L.L.C. acquired a new stake in DBV Technologies in the 2nd quarter valued at about $9,659,000. MPM Bioimpact LLC purchased a new position in shares of DBV Technologies during the 2nd quarter worth approximately $9,649,000. Octagon Capital Advisors LP acquired a new position in shares of DBV Technologies in the second quarter worth $9,315,000. Finally, Millennium Management LLC raised its stake in DBV Technologies by 26.1% in the 3rd quarter. Millennium Management LLC now owns 337,863 shares of the company’s stock valued at $3,379,000 after purchasing an additional 69,849 shares during the last quarter. 71.74% of the stock is currently owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.

Further Reading